Collins Helen Louise 4
4 · Enliven Therapeutics, Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Enliven (ELVN) CMO Helen Collins Exercises Options, Sells Shares
What Happened
- Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics (ELVN), exercised stock options for 5,000 shares at $2.48 per share (cost $12,400) and sold 5,000 shares in open-market trades the same day for total gross proceeds of approximately $219,017 (three blocks: 1,268 / 2,599 / 1,133 shares). The filing also shows a conversion/settlement of 5,000 RSUs (restricted stock units) into shares (no cash reported).
- The sales were executed June 17, 2026 and were carried out under a Rule 10b5-1 trading plan adopted by Collins on October 19, 2025.
Key Details
- Transaction date: June 17, 2026; Form 4 filed June 22, 2026.
- Option exercise: 5,000 shares acquired at $2.48 each (total $12,400). Footnote confirms all option shares were fully vested and exercisable as of the date.
- Open-market sales: total 5,000 shares sold in multiple trades for aggregate proceeds of ~ $219,017:
- 1,268 shares at a weighted avg $42.83 (proceeds ≈ $54,305; trades ranged $42.295–$43.2752)
- 2,599 shares at a weighted avg $43.87 (proceeds ≈ $114,018; trades ranged $43.30–$44.2925)
- 1,133 shares at a weighted avg $44.74 (proceeds ≈ $50,694; trades ranged $44.3005–$44.95)
- RSU conversion: 5,000 RSUs converted to shares (each RSU represents a contingent right to one share); no cash shown for that line.
- Filing notes: sales/exercise effected pursuant to a 10b5-1 plan (adopted Oct 19, 2025). The filing shows weighted-average prices and includes footnotes offering to provide per-trade price details upon request.
- Shares owned after transaction: not disclosed in the filing.
Context
- Derivative explanation: “M” indicates option exercise/derivative conversion — Collins exercised options to acquire shares. Because option exercise and sales occurred on the same day, the transactions functionally monetize vested option shares (often called a cashless exercise/monetization when shares are sold immediately).
- 10b5-1 plan: sales under an established 10b5-1 plan are pre-set and generally indicate routine selling, not necessarily a change in insider view.
- Timeliness: Form 4 was filed on June 22 for transactions dated June 17. Form 4s are normally due within two business days of a transaction; investors may want to confirm whether the filing was deemed timely by the SEC.
Insider Transaction Report
Form 4
Collins Helen Louise
CHIEF MEDICAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
[F1][F2]2026-06-17$2.48/sh+5,000$12,400→ 30,000 total - Sale
Common Stock
[F1][F3][F2]2026-06-17$42.83/sh−1,268$54,305→ 28,732 total - Sale
Common Stock
[F1][F4][F2]2026-06-17$43.87/sh−2,599$114,018→ 26,133 total - Sale
Common Stock
[F1][F5][F6]2026-06-17$44.74/sh−1,133$50,694→ 25,000 total - Exercise/Conversion
Stock Option (right to buy)
[F1][F7]2026-06-17−5,000→ 121,268 totalExercise: $2.48Exp: 2031-06-17→ Common Stock (5,000 underlying)
Footnotes (7)
- [F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
- [F2]Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- [F3]This transaction was executed in multiple trades at prices ranging from $42.295 to $43.2752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F4]This transaction was executed in multiple trades at prices ranging from $43.30 to $44.2925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F5]This transaction was executed in multiple trades at prices ranging from $44.3005 to $44.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F6]These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- [F7]All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Signature
/s/ Ben Hohl, by power of attorney|2026-06-22